ClinicalTrials.gg
CompletedNCT02798796BREAST-MRIUpdated Oct 23, 2026

Brazilian Randomized Study - Impact of MRI for Breast Cancer

An interventional study of MRI in Breast Cancer, sponsored by University of Sao Paulo General Hospital. Completed at 1 site in Brazil. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Nov 2014, registered Aug 2015).
Updated Oct 23, 2026Now CompletedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 351 studies in Breast Neoplasms with a site in Brazil — 52 open to participants now, 111 under way, 62 of them phase 3. Breast Neoplasms · Brazil.

Enrollment
116th of 309
446 · median 250
Started
2014
with 12 others
No phase
78 of 351
13 open now
Registered
149th of 351
by date

Among the 351 studies in Breast Neoplasms with a site in Brazil, this one is the 116th largest by enrollment of the 309 interventional ones that give a count, is one of 13 that started in 2014, is one of 78 with no phase, and was the 149th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

52 of the 351 studies in Breast Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Breast Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the ability of MRI to select patients for conservative treatment of breast cancer. Participants: female, over 18 years with breast cancer, stages I, II and III candidates for conservative surgery will be randomly randomized to do MRI or not according mammary density.

Read the detailed description

The aim of this study is to evaluate the ability of MRI to select patients for conservative treatment of breast cancer.An accurate assessment of the tumor is essential to select the best therapeutic strategy in the treatment of breast cancer.Currently, mammography, ultrasound and clinical examination are the standard techniques to assess the extent and location of the tumor.However, these imaging methods fail to assess the real size in approximately one third of patients eligible to conservative treatment.MRI has high sensitivity (95-100%) in the detection of invasive cancers as well as being able to detect hidden tumors, multifocality, multicentricity and cancer in the contralateral breast more often and greater accuracy than mammography or ultrasound.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • conservative surgery
  • MRI
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female,
  • Over 18 years with breast cancer
  • breast cancer stage 0 to III according to AJCC 7th Edition guideline

Exclusion criteria

Exclusion Criteria:

  • for breast MRI (ex. Metal implant)
  • Claustrophobia
  • Impossibility to stay in the prone position for more than an hour
  • History of allergic reaction to the paramagnetic contrast
  • History of chronic kidney disease on dialysis
  • Personal history of breast cancer treated surgically in the last 12 months.
  • Pregnancy or breastfeeding past 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
446 participants (actual)

Study arms

  • Experimental
    MRI Group

    MRI Group - all patients will be submitted to clinical examination, mammography and / or ultrasound, and breast MRI

    Device: MRI

  • No intervention
    Control Group

    Control group - all patients will be submitted to clinical examination, mammography and / or ultrasound of the breasts.

Interventions

  • DeviceMRI

    All patients will be submitted to MRI

06

What researchers measure

Primary outcomes

  1. local relapse-free survival

    presence of local and regional relapse during the follow up time

    Time frame: 5 years

Secondary outcomes

  1. overall survival between groups

    Time frame: 5 years

  2. disease free-survival between groups

    Time frame: 5 years

  3. Describe the percentage surgical change from conservative surgery to mastectomy

    Time frame: 6 months

  4. MRI findings in modifying the surgical management

    The proportion of patients whose surgical approach was modified to mastectomy

    Time frame: 6 months

  5. reoperation rates

    Time frame: 6 months

07

Study locations

1 site
  • Universidade de São Paulo
    São Paulo, São Paulo 01246903, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in May 2025, 126 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 126 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Nov 2016 → May 2025 and completion Nov 2016 → May 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2015
First posted
Jun 14, 2016
StartActual
Nov 2014
Primary completionActual
May 2025was Nov 2016
CompletionActual
May 2025was Nov 2016
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 23, 2026
Sites
1 site added, 1 site removed
Show site
  • Universidade de São Paulo · São Paulo, Brazil
Show 1 removed
  • Universidade de São Paulo · São Paulo, Brazil
Oct 23, 2026
Primary completion
Nov 2016→May 2025 (actual)
Oct 23, 2026
Study completion
Nov 2016→May 2025 (actual)
Oct 23, 2026
Enrollment
372 (estimated)→446 (actual)
Oct 23, 2026
Eligibility
1 inclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • RemovedClinical stages I, II and III candidates for conservative surgery
  • Addedbreast cancer stage 0 to III according to AJCC 7th Edition guideline
Oct 23, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore False positive rate, false negative rate, positive predictive value and negative predictive value MRI in the Breast Cancer conservative surgeryNow local relapse-free survivalTime frame: 3 years → 5 years
Oct 23, 2026
Secondary outcomes
1 time frame changed, 4 added, 5 removed
What changed in the outcomes
  • Addedoverall survival between groupsTime frame: 5 years
  • Addeddisease free-survival between groupsTime frame: 5 years
  • AddedMRI findings in modifying the surgical managementTime frame: 6 months
  • Addedreoperation ratesTime frame: 6 months
  • RemovedDescribe the percentage of positive margins on pathological examinationTime frame: 3 years
  • RemovedDescribe the percentage of additional surgery ratesTime frame: 3 years
  • RemovedCalculate the False positive rate, false negative rate , positive predictive value and negative predictive value according mammographic density, molecular subtype and histopathology of the tumorTime frame: 3 years
  • RemovedCalculate the period after successful treatment in which there is no appearance of the symptoms or effects of the disease after 3 and 5 years bettwen groupsTime frame: 5 years
  • RemovedCalculate how much is the cost to do the exam considering the false positive and false negative ratesTime frame: 3 years
  • Time frameDescribe the percentage surgical change from conservative surgery to mastectomy3 years → 6 months
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Status unknown→Completed
    1 site added, 1 site removed
    Show site
    • Universidade de São Paulo · São Paulo, Brazil
    Show 1 removed
    • Universidade de São Paulo · São Paulo, Brazil
    Primary completion Nov 2016→May 2025 (now actual)
    Study completion Nov 2016→May 2025 (now actual)
    Enrollment 372 (estimated)→446 (actual)
    Eligibility 1 inclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedClinical stages I, II and III candidates for conservative surgery
    • Addedbreast cancer stage 0 to III according to AJCC 7th Edition guideline
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore False positive rate, false negative rate, positive predictive value and negative predictive value MRI in the Breast Cancer conservative surgeryNow local relapse-free survivalTime frame: 3 years → 5 years
    Secondary outcomes 1 time frame changed, 4 added, 5 removed
    What changed in the outcomes
    • Addedoverall survival between groupsTime frame: 5 years
    • Addeddisease free-survival between groupsTime frame: 5 years
    • AddedMRI findings in modifying the surgical managementTime frame: 6 months
    • Addedreoperation ratesTime frame: 6 months
    • RemovedDescribe the percentage of positive margins on pathological examinationTime frame: 3 years
    • RemovedDescribe the percentage of additional surgery ratesTime frame: 3 years
    • RemovedCalculate the False positive rate, false negative rate , positive predictive value and negative predictive value according mammographic density, molecular subtype and histopathology of the tumorTime frame: 3 years
    • RemovedCalculate the period after successful treatment in which there is no appearance of the symptoms or effects of the disease after 3 and 5 years bettwen groupsTime frame: 5 years
    • RemovedCalculate how much is the cost to do the exam considering the false positive and false negative ratesTime frame: 3 years
    • Time frameDescribe the percentage surgical change from conservative surgery to mastectomy3 years → 6 months
    + 5 other changes: verification date, design details, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02798796
Responsible party
Sponsor
First posted
Jun 14, 2016
Start date
Nov 2014
Primary completion
May 2025
Completion
May 2025
Last update
Oct 23, 2026

Study contacts

Bruna Salani Mota, Recruiting
principal investigator · University of Sao Paulo General Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion